As of 2024-12-15, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -3.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 67.94 mil USD. LCTX's TTM EBITDA according to its financial statements is -20.78 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2024-12-13 | -3.27 |
| 2024-12-12 | -3.40 |
| 2024-12-11 | -4.24 |
| 2024-12-10 | -4.19 |
| 2024-12-09 | -4.12 |
| 2024-12-06 | -3.99 |
| 2024-12-05 | -3.86 |
| 2024-12-04 | -3.42 |
| 2024-12-03 | -3.64 |
| 2024-12-02 | -4.02 |
| 2024-11-29 | -3.87 |
| 2024-11-27 | -3.84 |
| 2024-11-26 | -4.17 |
| 2024-11-25 | -3.89 |
| 2024-11-22 | -3.25 |
| 2024-11-21 | -4.12 |
| 2024-11-20 | -4.50 |
| 2024-11-19 | -6.88 |
| 2024-11-18 | -6.66 |
| 2024-11-15 | -6.53 |
| 2024-11-14 | -6.71 |
| 2024-11-13 | -6.97 |
| 2024-11-12 | -7.29 |
| 2024-11-11 | -7.25 |
| 2024-11-08 | -7.07 |
| 2024-11-07 | -6.90 |
| 2024-11-06 | -7.08 |
| 2024-11-05 | -6.35 |
| 2024-11-04 | -6.29 |
| 2024-11-01 | -6.08 |
| 2024-10-31 | -6.23 |
| 2024-10-30 | -6.42 |
| 2024-10-29 | -6.68 |
| 2024-10-28 | -6.67 |
| 2024-10-25 | -6.31 |
| 2024-10-24 | -6.45 |
| 2024-10-23 | -6.58 |
| 2024-10-22 | -6.72 |
| 2024-10-21 | -6.54 |
| 2024-10-18 | -6.92 |
| 2024-10-17 | -6.29 |
| 2024-10-16 | -6.61 |
| 2024-10-15 | -6.24 |
| 2024-10-14 | -6.48 |
| 2024-10-11 | -6.44 |
| 2024-10-10 | -6.35 |
| 2024-10-09 | -6.67 |
| 2024-10-08 | -6.56 |
| 2024-10-07 | -6.62 |
| 2024-10-04 | -6.94 |